Persistence of rilpivirine following single dose of long-acting injection

被引：0
|
作者：
McGowan, I. [1 ]
Siegel, A. [2 ]
Engstrom, J. [2 ]
Nikiforov, A. [2 ]
Duffill, K. [2 ]
Edick, S. [1 ]
Mitchell, C. [1 ]
Back, D. [3 ]
Else, L. [3 ]
Egan, D. [3 ]
Khoo, S. [3 ]
Williams, P. [4 ]
Brand, R. M. [1 ]
Cranston, R. D. [1 ]
机构：
[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[2] Magee Womens Res Inst, Pittsburgh, PA USA
[3] Univ Liverpool, Liverpool, Merseyside, England
[4] Janssen Pharmaceut, Beerse, Belgium
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
TUAC0103
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Formulation and pharmacology of long-acting rilpivirine
    Williams, Peter E.
    Crauwels, Herta M.
    Basstanie, Esther D.
    CURRENT OPINION IN HIV AND AIDS, 2015, 10 (04) : 233 - 238
  • [2] Long-acting rilpivirine for HIV prevention
    Jackson, Akil
    McGowan, Ian
    CURRENT OPINION IN HIV AND AIDS, 2015, 10 (04) : 253 - 257
  • [3] In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
    Rajith K. R. Rajoli
    David J. Back
    Steve Rannard
    Caren Freel Meyers
    Charles Flexner
    Andrew Owen
    Marco Siccardi
    Clinical Pharmacokinetics, 2018, 57 : 255 - 266
  • [4] In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
    Rajoli, Rajith K. R.
    Back, David J.
    Rannard, Steve
    Meyers, Caren Freel
    Flexner, Charles
    Owen, Andrew
    Siccardi, Marco
    CLINICAL PHARMACOKINETICS, 2018, 57 (02) : 255 - 266
  • [5] Creation of a long-acting rilpivirine prodrug nanoformulation
    Hilaire, James R.
    Bade, Aditya N.
    Sillman, Brady
    Gautam, Nagsen
    Herskovitz, Jonathan
    Shetty, Bhagya Laxmi Dyavar
    Wojtkiewicz, Melinda S.
    Szlachetka, Adam
    Lamberty, Benjamin G.
    Sravanam, Sruthi
    Fox, Howard S.
    Alnouti, Yazen
    Dash, Prasanta K.
    McMillan, JoEllyn M.
    Edagwa, Benson J.
    Gendelman, Howard E.
    JOURNAL OF CONTROLLED RELEASE, 2019, 311 : 201 - 211
  • [6] Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV
    Thoueille, Paul
    Saldanha, Susana Alves
    Schaller, Fabian
    Choong, Eva
    Veuve, Francois
    Munting, Aline
    Cavassini, Matthias
    Braun, Dominique
    Gunthard, Huldrych F.
    Ramirez, Jessy J. Duran
    Surial, Bernard
    Furrer, Hansjakob
    Rauch, Andri
    Ustero, Pilar
    Calmy, Alexandra
    Stockle, Marcel
    Di Benedetto, Caroline
    Bernasconi, Enos
    Schmid, Patrick
    Marzolini, Catia
    Girardin, Francois R.
    Buclin, Thierry
    Decosterd, Laurent A.
    Guidi, Monia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [7] Rilpivirine long-acting for the prevention and treatment of HIV infection
    Ferretti, Francesca
    Boffito, Marta
    CURRENT OPINION IN HIV AND AIDS, 2018, 13 (04) : 300 - 307
  • [8] Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers
    Verloes, R.
    Deleu, S.
    Niemeijer, N.
    Crauwels, H.
    Meyvisch, P.
    Williams, P.
    HIV MEDICINE, 2015, 16 (08) : 477 - 484
  • [9] Implementing long-acting injectable cabotegravir and rilpivirine in Africa
    Orkin, Chloe
    Ring, Kyle
    LANCET INFECTIOUS DISEASES, 2024, 24 (10): : 1060 - 1061
  • [10] Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice
    Borghetti, Alberto
    Farinacci, Damiano
    Ciccullo, Arturo
    Dusina, Alex
    Moschese, Davide
    Iannone, Valentina
    D'Angelillo, Anna
    Lombardi, Francesca
    Delle Donne, Valentina
    Massaroni, Valentina
    Visconti, Elena
    Tamburrini, Enrica
    Di Giambenedetto, Simona
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (10) : 4970 - 4974
12345